Efficacy and safety of antithymocyte globulin treatment of steroid-resistant acute rejection in kidney transplantation.
Bertoni
E
E
Renal Unit, Careggi University Hospital, Florence, Italy.
Maccario
M
M
Biagini
M
M
Montagnino
G
G
Piperno
R
R
Tarantino
A
A
Salvadori
M
M
D000328:Adult; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000401:mortality; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012189:Retrospective Studies; D012449:Safety; D013256:Steroids / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D013256:Steroids; D009173:Mycophenolic Acid